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BET bromodomain proteins are important epigenetic regulators of gene expression
that bind acetylated histone tails and regulate the formation of acetylation-dependent
chromatin complexes. BET inhibitors suppress inflammatory responses in multiple cell
types and animal models, and protect against bone loss in experimental periodontitis in
mice. Here, we analyzed the role of BET proteins in inflammatory activation of gingival
fibroblasts (GFs) and gingival epithelial cells (GECs). We show that the BET inhibitors
I-BET151 and JQ1 significantly reduced expression and/or production of distinct, but
overlapping, profiles of cytokine-inducible mediators of inflammation and bone resorption
in GFs from healthy donors (IL6, IL8, IL1B, CCL2, CCL5, COX2, and MMP3) and the
GEC line TIGK (IL6, IL8, IL1B, CXCL10, MMP9) without affecting cell viability. Activation
of mitogen-activated protein kinase and nuclear factor-κB pathways was unaffected
by I-BET151, as was the histone acetylation status, and new protein synthesis was
not required for the anti-inflammatory effects of BET inhibition. I-BET151 and JQ1 also
suppressed expression of inflammatory cytokines, chemokines, and osteoclastogenic
mediators in GFs and TIGKs infected with the key periodontal pathogen Porphyromonas
gingivalis. Notably, P. gingivalis internalization and intracellular survival in GFs and TIGKs
remained unaffected by BET inhibitors. Finally, inhibition of BET proteins significantly
reduced P. gingivalis-induced inflammatory mediator expression in GECs and GFs from
patients with periodontitis. Our results demonstrate that BET inhibitors may block the
excessive inflammatory mediator production by resident cells of the gingival tissue and
identify the BET family of epigenetic reader proteins as a potential therapeutic target in
the treatment of periodontal disease.
Keywords: periodonditis, BET bromodomain, gingival fibroblast, gingival epithelial cell, porphyromonas gingivalis,
I-BET151, chronic inflammation
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INTRODUCTION
Periodontitis is an inflammatory disease of the periodontium
caused by microbial imbalance (dysbiosis) and the anaerobic
bacterium Porphyromonas gingivalis plays a central role in
driving the chronic inflammation (1). Oral pathogen interaction
with gingival cells and infiltrating immune cells leads to a
local immune response which fails to eradicate the invading
bacteria which are equipped with sophisticated mechanisms of
immune evasion. If unresolved, ongoing inflammation leads to
periodontal ligament degradation, bone resorption and eventual
tooth loss (2). Resident cells of the gingival tissue, including
gingival epithelial cells (GECs) and gingival fibroblasts (GFs),
represent the first line of defense against oral pathogens
and are considered an important component of the innate
immune system (3, 4). However, their chronic activation due
to persistent interaction with oral bacteria, which involves the
secretion of large quantities of cytokines, chemokines, matrix-
degrading enzymes, and prostaglandins, significantly contributes
to periodontitis pathogenesis (5).
Expression of inflammatory mediators is tightly regulated by
epigenetic mechanisms, among which reversible acetylation of
histone proteins plays a critical role. Importantly, pathological
changes in histone acetylation and in expression of histone-
modifying enzymes, histone acetyltransferases (HATs) and
histone deacetylases (HDACs), have been identified in
periodontitis patients and in a mouse model of periodontal
disease (6, 7). Bromodomain proteins, 46 of which have
been identified in the human genome, recognize ε-N-lysine
acetylation motifs on histone tails and regulate the formation of
acetylation-dependent chromatin complexes that are required
for transcription (8). In particular, the ubiquitously expressed
proteins BRD2, BRD3, BRD4, which belong to the bromodomain
and extraterminal domain (BET) family, play distinct roles in
coupling histone acetylation to gene transcription (9), including
transcriptional activation of inflammatory genes (10). BET
proteins are critical regulators of transcriptional elongation and
cell division, and dysregulation of BET protein function, such
as pathogenic chromosomal BRD4 translocations, has been
identified in oncological conditions (11). BET proteins have
thus emerged as potential therapeutic targets, and compounds
targeting their tandem bromodomains are currently being
evaluated in clinical trials (12).
The discovery of specific BET inhibitors acting as acetylated
histone mimetics, I-BET151, and JQ1 (13, 14), has not only
allowed for therapeutic targeting of BET proteins in cancer,
but also provided insight into contributions of bromodomain-
containing proteins to the pathogenesis of inflammatory
disorders that are associated with an altered epigenetic landscape
(15). BET inhibitors suppress lipopolysaccharide (LPS)- and
cytokine-induced expression of inflammatory cytokines and
chemokines in monocytes and macrophages in vitro and in vivo,
and protect mice from lethal endotoxic shock and sepsis (16, 17).
Inhibition of BET proteins also ameliorates inflammation and
resulting pathology in animal models of several inflammatory
diseases, including rheumatoid arthritis (RA), graft-vs. host
disease and multiple sclerosis (18–20). Surprisingly, despite
extensive efforts toward understanding bromodomain protein
function in health and disease, little is still known about the role
of BET proteins in the pathogenesis of periodontitis. The only
study available to date demonstrated that the BET inhibitor JQ1
ameliorates gingival inflammation and alveolar bone destruction
in P. gingivalis-induced experimental periodontitis in mice (21).
In this model, the therapeutic effects of BET inhibition were
attributed to diminished inflammatory cytokine production by
macrophages and reduced osteoclast formation (21). However,
the influence of JQ1 on other cell types involved in periodontitis
pathogenesis has not been tested. In the present study, we
investigated the effects of the BET bromodomain inhibitors I-
BET151 and JQ1 on inflammatory and antimicrobial responses of
resident cells of the gingival tissue, GFs and GECs, in the context
of infection with the periodontal pathogen P. gingivalis.
MATERIALS AND METHODS
Subjects, Cell Isolation, and Culture
Gingival tissue specimens for primary cell isolation were
collected from healthy individuals undergoing orthodontic
treatment (n = 9) and from patients with chronic periodontitis
(n= 5) at the Department of Periodontology and Oral Medicine,
Faculty of Medicine, Jagiellonian University Medical College
in Kraków, Poland. This study was approved by and carried
out in accordance with the recommendations of the Bioethical
Committee of the Jagiellonian University in Kraków, Poland
(permit numbers 122.6120.337.2016 and KBET/310/B/2012). All
subjects gave written informed consent in accordance with
the Declaration of Helsinki. Clinical characteristics of patients
included in the study are shown in Supplementary Table 1.
The epithelial layer was separated enzymatically by treatment
with dispase at 4◦C overnight (o/n) and subjected to three
rounds of digestion with trypsin (BioWest) for 10min at 37◦C.
After centrifugation, the obtained GECs were suspended in
keratinocyte growth medium (KGM-Gold, Lonza) and cultured
in 6-well plates until confluence. GFs were isolated from the
remaining connective tissue by digestion with 0.1% collagenase
I (Invitrogen) at 37◦C o/n. Cells were then vigorously pipetted,
washed in PBS, suspended in Dulbecco’s modified Eagle’s
medium (DMEM, Lonza) supplemented with 10% fetal bovine
serum (FBS, EuroClone), 50U/ml penicillin/streptomycin and
50 U/ml gentamicin, and cultured in T75 flasks. Cells were
cultured in the presence of 10µg/ml nystatin until passage 2
to prevent fungal contamination. The isolation procedure and
the homogeneity of GF cultures have been standardized and
described previously (22). GECs were used for experiments
at passage 2 and GFs were used between passages 4 and
9. Telomerase-immortalized gingival keratinocytes (TIGKs,
RRID:CVCL_M095) were kindly provided by Prof. Richard
J Lamont (University of Louisville School of Dentistry) (23)
and were cultured in KGM-Gold. One day prior to and
during experiments, GFs were cultured in antibiotic-free DMEM
containing 2% FBS, whereas TIGKs and primary GECs were
cultured in antibiotic-free KGM-Gold.
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Bacterial Culture and Cell Infection
Porphyromonas gingivalis wild-type strain ATCC 33277 was
grown on blood agar plates as described elsewhere (24). After
anaerobic culture for 5–7 days at 37◦C, bacteria were inoculated
into brain–heart infusion (BHI) broth (Becton Dickinson)
supplemented with 0.5 mg/ml L-cysteine, 10µg/ml hemin and
0.5µg/ml vitamin K, and cultured o/n in an anaerobic chamber
(85% N2, 10% CO2, and 5% H2). Bacteria were then washed in
PBS, resuspended in fresh BHI broth at optical density (OD)600nm
= 0.1 and cultured for∼20 h. A bacterial suspension at OD600nm
= 1 [corresponding to 109 colony-forming units (CFU)/ml]
in PBS was prepared and used for experiments. In some
experiments, bacteria were heat-inactivated by 30min incubation
at 60◦C or were treated with specific gingipain inhibitors KYT-
1 and KYT-36 (Peptide Institute Inc.). 1µM KYT-1 and KYT-36
were incubated with bacteria for 20min at 37◦C prior to infection
and were added to culture media for the duration of infection.
RNA Isolation and Quantitative (q)PCR
GFs and TIGKs were seeded at 2.5 × 105 cells per well in
12-well plates and after o/n culture were treated with DMSO
[0.005% (V/V)] (BioShop), 1µM I-BET151 (TargetMol) or
1µM JQ1 (Abcam) for 30min followed by stimulation with
TNF, IL-1β (10 ng/ml, both from BioLegend) or infection with
P. gingivalis at a multiplicity of infection (MOI) of 100 for 4 h. In
some experiments, protein synthesis was blocked with 10µg/ml
cycloheximide (CHX, TargetMol). Total RNA was isolated
using an EZ-10 Spin Column Total RNA Minipreps Super Kit
(Bio-Basic), quantified using a Nanodrop spectrophotometer
(Thermo Scientific) and equivalent amounts of RNA (500–
1,000 ng) were converted to cDNA using a High-Capacity
cDNA Reverse Transcription Kit (Applied Biosystems). qPCR
reactions were performed on a CFX96 TouchTM Real-Time PCR
Detection System (BIO-RAD) using PowerUp SybrGreen PCR
mix (Applied Biosystems) and primers (Genomed S.A.) listed
in Supplementary Table 2. The data were analyzed using the
CFX Manager (BIO-RAD) and changes in mRNA expression
were calculated relative to RPLP0 (ribosomal protein lateral
stalk subunit P0) expression using the 11CT method unless
otherwise indicated.
ELISA
GFs and TIGKs were seeded at 5.0 × 104 cells per well in
48-well plates and after o/n culture were treated with DMSO
[0.005% (V/V)], I-BET151 or JQ1 (both at 100 nM−1µM) for
30min before stimulation with TNF or IL-1β (10 ng/ml), or
infection with heat-inactivated or KYT-treated P. gingivalis for
24 h. Alternatively, after treatment with inhibitors, GFs were
infected with P. gingivalis at an MOI of 100 for 1 h. Cells were
then washed 3 times with PBS and cultured in fresh medium
containing DMSO, I-BET151, or JQ1 for another 24 h prior to
collection of supernatants. Cell-free culture supernatants were
collected and concentrations of IL-6, IL-8, CCL2, and CCL20
were determined using ELISA MAX kits (BioLegend) according
to the manufacturer’s instructions. Absorbance was measured
using an Infinite M200 microplate reader (Tecan).
Measurement of Cell Viability
Cell viability was assessed using the MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, Sigma-
Aldrich) reduction assay as described previously (25).
Immunoblotting
Cell lysates were prepared in 1x Laemmli’s buffer (2%
SDS, 10% glycerol, 125mM Tris-HCl, pH 6.8) and protein
content was quantitated using the Bradford assay (BioShop).
In some experiments, cells treated with the HDAC inhibitor
suberoylanilide hydroxamic acid (SAHA, 5µM) (Abcam) were
used as a positive control. Equivalent amounts of protein
were resolved by electrophoresis on 10 or 15% polyacrylamide
gels and transferred to the Immobilon-PSQ PVDF membranes
(Millipore). Membranes were then blocked in 2%milk (BioShop)
in TBS containing 0.1% Tween-20 (BioShop) (TBS/T), and
incubated at 4◦C o/n with primary antibodies recognizing
acetylated lysine, acetyl-histone 3 (Ac-H3), H3, IκBα, phospho
(p)-p38, p-ERK, p-p65 (all from Cell Signaling Technology), or
tubulin (clone DM1A, Sigma-Aldrich). After washing in TBS/T,
membranes were incubated with horseradish peroxidase (HRP)–
conjugated anti-mouse or anti-rabbit Ig secondary antibodies
(Dako) and developed with a Clarity Western ECL Substrate
(BIO-RAD). Visualization was performed using a ChemiDocMP
Imaging System and the ImageLab software (BIO-RAD).
Measurement of Bacterial Internalization
and Survival—Colony-Forming Assay
Cells were treated with 0.005% (V/V) DMSO or 1µM I-BET151
in triplicate wells for 20 h prior to infection with P. gingivalis at an
MOI of 100 for 1 h. Cells were then washed 3 times with PBS and
were either lysed immediately in sterile distilled water for 20min
or cultured in fresh medium containing DMSO or I-BET151 for
another 24 h before lysis. Cell lysates were serially diluted and
10µl of each dilution was plated in duplicate on blood agar plates
and cultured for 5–7 d anaerobically at 37◦C. Bacterial colonies
were counted and the data were expressed as CFU per cell.
Statistical Analyses
Data are presented as the mean +SEM. In studies of primary
GFs and GECs, n’s represent cell lines from individual
donors/patients, while in TIGK studies n’s refer to independent
experiments. Parametric tests were used for comparisons
between groups (ratio paired t-test or one-way ANOVA followed
by Bonferroni multiple comparison test, where appropriate). p <
0.05 were considered statistically significant.
RESULTS
BET Inhibitors Suppress Cytokine-Induced
Inflammatory Activation of GFs and TIGKs
We initiated this study by investigating whether BET
bromodomain proteins are involved in GF inflammatory
activation in response to cytokines that are present in the
inflamed gingival tissue. Primary GFs from healthy individuals
were stimulated with TNF or IL-1β in the presence of the BET
inhibitor I-BET151. BET inhibition significantly suppressed
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FIGURE 1 | BET inhibitors suppress cytokine-induced gingival fibroblast (GF) inflammatory activation without affecting cell viability. (A) Relative mRNA expression of
IL8, IL6, IL1B, CCL2, CCL5, MMP3, COX2, and CCL20 in GFs treated with DMSO or 1µM I-BET151 for 30min prior to simulation with TNF or IL-1β (both at
10 ng/ml) for 4 h analyzed by qPCR (mean + SEM; n = 4–5). *P < 0.05, **P < 0.01, ***P < 0.001; ratio paired t-test. (B) IL-8, CCL2, and CCL20 production by GFs
treated with DMSO or I-BET151 or JQ1 at two different concentrations (100 nM and 1µM) for 30min prior to simulation with TNF or IL-1β (both 10 ng/ml) for 24 h
determined by ELISA (mean concentration + SEM; n = 5). (C) Viability of GFs (n = 3) treated with DMSO, I-BET151, or JQ1 (both at 1µM) for 30min prior to
simulation with 10 ng/ml TNF or IL-1β for 24 h assessed using MTT assay and presented as % of control + SEM.
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FIGURE 2 | BET inhibitors reduce cytokine-induced inflammatory mediator production by telomerase-immortalized gingival keratinocytes (TIGKs) without affecting cell
viability. (A) Relative mRNA expression of IL8, IL6, IL1B, CXCL10, MMP9, and CCL20 in TIGKs treated with DMSO or 1µM I-BET151 for 30min prior to simulation
with TNF or IL-1β (both at 10 ng/ml) for 4 h determined by qPCR (mean + SEM; n = 4–5). *P < 0.05, **P < 0.01, ***P < 0.001; ratio paired t-test. (B) IL-6, IL-8, and
CCL20 production by TIGKs treated with DMSO or increasing concentrations (100 nM, 500 nM, and 1µM) of I-BET151 or JQ1 for 30min followed by simulation with
10 ng/ml TNF (left panel) or 10 ng/ml IL-1β (right panel) for 24 h measured by ELISA (mean concentration + SEM; n = 5). (C) Viability of TIGKs (n = 3) treated with
DMSO or 1µM I-BET151 for 30min prior to simulation with TNF or IL-1β (both 10 ng/ml) for 24 h analyzed using MTT assay and shown as % of control + SEM.
cytokine-induced mRNA expression of a broad range of
inflammatory mediators involved in the pathogenesis of
periodontitis, including IL8, IL1B, CCL2, CCL5, MMP3, and
COX2 (Figure 1A). Interestingly, some selectivity of I-BET151
effects on GF gene expression was noted, as I-BET151 suppressed
IL-1β-, but not TNF-induced IL6 expression, and, surprisingly,
promoted expression of the antimicrobial chemokine CCL20 in
response to TNF stimulation. In the absence of inflammatory
stimulation, I-BET151 significantly reduced mRNA levels
of IL1B and CCL2, whereas expression of other mediators
included in our analyses remained unaffected (Figure 1A).
Next, to test if effects of BET inhibition on mRNA expression
translate into changes in protein levels, we treated GFs with
I-BET151 or a chemically unrelated BET inhibitor, JQ1, prior to
24 h cytokine stimulation. Both compounds dose-dependently
suppressed TNF- and IL-1β-induced IL-8 and CCL2 production,
reaching up to 70% inhibition at 1µM. JQ1 displayed more
potent inhibitory activity, significantly suppressing IL-8 and
CCL2 secretion already at 100 nM (Figure 1B). In contrast,
BET inhibition had no significant effects on agonist-induced
CCL20 production, though a trend toward increased CCL20
secretion in the presence of TNF stimulation was noted
(Figure 1B), consistent with mRNA data. To exclude the
possibility that the observed effects of BET inhibitors on GF
activation could be attributed to compound cytotoxicity, GFs
were exposed to I-BET151 or JQ1 in the presence of cytokine
stimulation for 24 h. Both compounds had negligible effects
on cell viability as determined using the MTT reduction
assay (Figure 1C).
To verify whether BET inhibitors similarly modulate
inflammatory responses of GECs, we utilized TIGKs, an
immortalized cell line derived from healthy donor GECs that
closely mimics primary cell responses (23). TNF and IL-1β
stimulation upregulated a cluster of inflammatory mediators in
TIGKs that was distinct from, but partly overlapping with that
observed in GFs. I-BET151 treatment significantly suppressed
cytokine-induced mRNA expression of IL8, IL6, IL1B, CXCL10,
and MMP9 (Figure 2A). Interestingly, BET inhibition reduced
not only inducible, but also basal levels of these transcripts.
Similar to observations in GFs, BET inhibition had limited
effect on CCL20 expression. Interestingly, the sensitivity of
individual genes to transcriptional suppression by I-BET151
differed between the two analyzed cell types: while I-BET151
reduced cytokine-induced IL6 mRNA accumulation by >90%
in TIGKs (Figure 2A), it had modest effects on IL6 expression
in GFs (Figure 1A), indicating differential requirements for
BET proteins in transcriptional induction of the same gene in
two different cell types. The observed effects of BET inhibition
were next confirmed at the protein level. I-BET151 and JQ1
dose-dependently reduced IL-6 and IL-8 accumulation in
cell culture supernatants, whereas CCL20 production was
moderately induced (Figure 2B). Maximum suppression of
IL-6 and IL-8 production by BET inhibitors was achieved at
100-500 nM, suggesting that TIGKs might be more sensitive to
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FIGURE 3 | I-BET151 has no effect on MAPK and NFκB activation in gingival fibroblasts (GFs) and new protein synthesis is not required for inflammatory gene
suppression by I-BET151. (A) Western blot analysis of phospho (p)-ERK, p-p38, IκBα, p-p65(Ser536), and tubulin (Tub) in total cell lysates of GFs after 30min
treatment with DMSO or 1µM I-BET151 followed by stimulation with 10 ng/ml TNF for 5, 20, or 60min. (B) Western blot analysis of total acetylated lysine (AcLys),
acetyl-histone H3(Lys18) (AcH3), acetyl-H4(Lys8) (AcH4), and total H3 in cell lysates of GFs treated with DMSO or 1µM I-BET151 for 30min prior to TNF (10 ng/ml)
stimulation for 4 or 24 h. Cells treated with SAHA for 4 h were used as a positive control for lysine hyperacetylation. Data representative of 2–3 independent
experiments are shown in (A,B). (C) Relative mRNA expression of IL1B, CCL2, and COX2 in GFs treated with DMSO or 1µM I-BET151 in the presence or absence of
cycloheximide (CHX) for 30min prior to simulation with 10 ng/ml TNF for 4 h analyzed by qPCR (mean + SEM; n = 4; % of suppression compared to DMSO control
are depicted in each graph).
low concentrations of BET inhibitors compared to GFs. In line
with previous observations in GFs, I-BET151, and JQ1 had no
effect on TIGK viability (Figure 2C).
BET Inhibitors Have No Effect on
Inflammatory Signaling Pathway Activation
in GFs and Do Not Require New Protein
Synthesis for Gene Suppression
Inhibition or silencing of BET proteins regulates gene
expression not only through disruption of interactions between
bromodomains and acetylated histones at individual gene
promoters, but also by affecting acetylation-dependent signaling
pathways, including mitogen-activated protein kinase (MAPK)
and NF-κB signaling (26, 27). We therefore analyzed the effects
of BET inhibition on TNF-induced activation of signaling
pathways critical for inflammatory cell activation and on protein
acetylation status. Treatment of primary GFs from healthy
donors with I-BET151 had no effect on p38 and extracellular
signal-regulated kinase (ERK) MAPK activation, degradation of
IκBα and phosphorylation of p65 NFκB subunit (Figure 3A).
I-BET151 also failed to affect histone H3 and H4 acetylation,
as well as the levels of total acetylated lysine detected in
cellular lysates (Figure 3B), excluding the possibility that BET
inhibitors could affect GF activation through off-target effects
on HATs or HDACs. Finally, we tested whether BET inhibitors
could affect gene expression indirectly by induction of gene
repressors in GFs. I-BET151 suppressed IL1B, CCL2, and COX2
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FIGURE 4 | BET inhibitors suppress production of inflammatory mediators by gingival fibroblasts (GFs) infected with P. gingivalis. (A) qPCR analysis of relative mRNA
expression of IL8, IL6, IL1B, CCL2, CCL5, MMP3, COX2, and CCL20 in GFs treated with DMSO, I-BET151 or JQ1 (both at 1µM) for 30min prior to infection with P.
gingivalis (MOI = 100) for 4 h (mean + SEM; n = 5–6). (B) Production of IL-8, IL-6 and CCL2 by GFs exposed to DMSO or I-BET151 or JQ1 at two different
concentrations (100 nM and 1µM) for 30min before P. gingivalis infection (MOI = 100) for 1 h, followed by washing and 24 h culture in fresh medium containing DMSO
or BET inhibitors (mean concentration + SEM; n = 5–6). (A,B) *P < 0.05, **P < 0.01, ***P < 0.001; one-way ANOVA followed by Bonferroni multiple comparison test.
(C) Intracellular survival of P. gingivalis in GFs treated with DMSO or 1µM I-BET151 for 20 h prior to infection with P. gingivalis (MOI = 100) for 1 h determined by
colony-forming assay immediately (1 h) or 24 h post-infection. Data are presented as mean colony-forming units (CFU)/cell + SEM of 4 independent experiments.
expression both in the absence or presence of the protein
synthesis inhibitor CHX (Figure 3C). Suppression of IL6 and
IL8 by I-BET151 in TNF-stimulated TIGKs was also unaffected
by CHX (Supplementary Figure 1), indicating that de novo
synthesis of repressor proteins is not necessary for suppression
of inflammatory mediators by BET inhibitors in both cell types.
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BET Inhibitors Suppress Inflammatory
Mediator Production by GFs and TIGKs
Infected With P. gingivalis
In periodontal disease, P. gingivalis directly interacts with
and invades resident cells of the gingival tissue, which not
only contributes to the chronicity of inflammation, but also
facilitates bacterial spreading to deeper tissues. To analyze
the role of BET proteins in GF and TIGK activation and
antimicrobial responses, cells were treated with I-BET151 or
JQ1 prior to infection with P. gingivalis. In primary GFs
from healthy donors, induction of inflammatory mediator
expression by P. gingivalis was comparable to, or even
higher than that observed following cytokine stimulation,
and BET inhibition significantly suppressed bacteria-induced
upregulation of IL8, IL1B, CCL2, CCL5, MMP3, and COX2,
but not CCL20 (Figure 4A). In line with previous observations,
JQ1 was more potent in blocking gene induction than I-
BET151. Although the kinetics of mRNA induction by P.
gingivalis differed between individual genes, I-BET151 uniformly
reduced IL8, IL1B, CCL2, and CCL5 expression at 4 and
24 h post-infection (Supplementary Figure 2). Production of IL-
8 and CCL2 protein by P. gingivalis-infected GFs was also
dose-dependently reduced by both BET inhibitors, whereas
suppression of IL-6 production was less pronounced (Figure 4B).
Next, to test whether BET inhibitors affect cellular response to
P. gingivalis infection, GFs were treated with I-BET151 for 20h
prior to infection with P. gingivalis for 1 h, and the presence
of live bacteria in cell lysates was determined using the colony-
forming assay. I-BET151 had no effect on the numbers of
bacteria detected in GFs immediately and 24 h post-infection
(Figure 4C), indicating that BET proteins are not involved
in internalization and elimination of intracellular P. gingivalis
by GFs.
Infection of TIGKs with P. gingivalis also led to transcriptional
upregulation of a set of inflammatory genes largely overlapping
with that induced by cytokines (Figure 5A). I-BET151 treatment
significantly reduced mRNA levels of IL8, IL6, IL1B, COX2,
and CXCL10, while leaving CCL20 expression unaffected
(Figure 5A). I-BET151 and JQ1 also significantly reduced
TIGK IL-6 and IL-8 production induced by exposure to
heat-inactivated P. gingivalis. Both compounds inhibited
IL-6 and IL-8 secretion by ∼85 and 40%, respectively,
already at 100 nM (Figure 5B). A similar degree of IL-6
and IL-8 inhibition by BET inhibitors was observed in
TIGKs infected with live P. gingivalis in the presence of
gingipain inhibitors that were used to eliminate the potential
confounding factor of cytokine degradation by bacterial
proteases (data not shown). Importantly, BET inhibitor effects
were restricted to inflammatory gene transcription as treatment
with I-BET151 for 20h prior to infection failed to affect P.
gingivalis internalization by TIGKs (Figure 5C), consistent
with previous observations in GFs. Collectively, these results
demonstrate that BET inhibitors suppress production of a
broad range inflammatory mediators by GFs and GECs without
affecting P. gingivalis internalization and survival within the
infected cells.
FIGURE 5 | BET inhibitors block inflammatory activation of
telomerase-immortalized gingival keratinocytes (TIGKs) infected with P.
gingivalis. (A) Relative mRNA expression of IL8, IL6, IL1B, COX2, CXCL10,
and CCL20 in TIGKs cultured for 30min with DMSO or I-BET151 (1µM)
followed by 4 h infection with P. gingivalis (MOI = 100) determined by qPCR
(mean + SEM; n = 4–5). *P < 0.05, **P < 0.01, ***P < 0.001; ratio paired
t-test. (B) Production of IL-6 and IL-8 by TIGKs treated with DMSO or
I-BET151 or JQ1 at two different concentrations (100 nM and 1µM) for 30min
prior to infection with heat-inactivated P. gingivalis (MOI = 100) for 24 h (mean
concentration + SEM; n = 4). *P < 0.05, **P < 0.01; one-way ANOVA
followed by followed by Bonferroni multiple comparison test. (C) Intracellular
survival of P. gingivalis in TIGKs treated with DMSO or 1µM I-BET151 for 20 h
before infection with P. gingivalis (MOI = 100) for 1 h determined by
colony-forming assay immediately after infection. Results are presented as
mean colony-forming units (CFU)/cell + SEM of 4 independent experiments.
BET Inhibitors Reduce Inflammatory Gene
Expression in GFs and GECs From Patients
With Periodontitis
GFs present in the inflamed gingival tissue in periodontitis
patients display an activated phenotype and hyperresponsiveness
to P. gingivalis infection in vitro (28, 29). We therefore examined
whether GFs isolated from patients with periodontitis were
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FIGURE 6 | Gingival fibroblasts (GFs) and gingival epithelial cells (GECs) from periodontitis patients are sensitive to the anti-inflammatory activity of BET inhibitors. (A)
Primary GFs from patients with periodontitis were treated with DMSO, I-BET151 or JQ1 (both at 1µM) for 30min prior to infection with P. gingivalis (MOI = 100) for 4 h
and mRNA levels of inflammatory mediators were determined by qPCR. Data for individual patients (PD1–PD4) are presented on a heat map as row Z-scores
calculated from 1Ct values relative to a housekeeping gene (RPLP0). (B) Comparison of inflammatory mediator induction in TIGKs and primary GECs from
periodontitis patients after 4 h infection with P. gingivalis (MOI = 100) (mean fold induction compared to uninfected cells + SEM; n = 3 for TIGKs vs. n = 3 GEC lines
from individual patients (PD1, PD2, PD5). (C) qPCR analysis of mRNA levels of inflammatory mediators in primary GECs from patients with periodontitis (PD1, PD2,
PD3, PD5) treated with DMSO or 1µM I-BET151 for 30min followed by infection with P. gingivalis (MOI = 100) for 4 h. Symbols represent relative expression values
from individual patients (n = 4). **P < 0.01, ***P < 0.001; ratio paired t-test.
resistant to the anti-inflammatory effects of BET inhibitors.
The degree of suppression of IL8, IL1B, CCL2, CCL5, MMP3,
and COX2 caused by I-BET151 or JQ1 in P. gingivalis-
infected GFs from periodontitis patients was comparable to that
observed in healthy donor GFs (Figure 6A). JQ1, but not I-
BET151, moderately reduced IL6 mRNA levels, consistent with
observations in GFs from healthy individuals, while CCL20
expression was upregulated by both BET inhibitors (Figure 6A).
Next, to assess the sensitivity of GECs from periodontitis patients
to BET inhibitors, we first compared the inflammatory gene
expression profile induced by P. gingivalis in TIGKs and primary
GECs. While a shared cluster of genes that included IL6, IL8,
IL1B, COX2, CXCL10, CCL20, and CCL2 was upregulated by P.
gingivalis in both types of cells, we also noted some differential
responses. The chemokines CCL3 and CCL5 were selectively
induced in GECs, but not in TIGKs, whereas expression of the
metalloproteinases MMP3 and MMP9 was upregulated upon P.
gingivalis infection only in TIGKs (Figure 6B). Treatment of
primary GECs from periodontitis patients with I-BET151 prior
to P. gingivalis infection resulted in significant suppression of
IL6, IL1B, CCL2, and COX2. However, in contrast to TIGKs, IL8,
and CXCL10 mRNA levels were not affected by BET inhibition,
whereasCCL20 expression was consistently induced (Figure 6C).
Together, these observations suggest that BET proteins play a key
role in regulating inflammatory mediator expression in GFs and
GECs in response to an oral pathogen.
DISCUSSION
A severe form of periodontitis affects approximately 10% of
the human population, leading to inevitable tooth loss if left
untreated, and is strongly associated with increased risk of
developing systemic diseases, including RA, atherosclerosis and
cancer (1, 30). Non-surgical treatment strategies conventionally
used to treat periodontitis, scaling and root planing, or
root surface debridement, focus solely on reducing bacterial
challenge, but in many patients are insufficient to fully resolve
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chronic inflammation. Because of that, there is a growing
need for identifying novel therapeutic strategies ameliorating
the host inflammatory response that could be used as an
adjunct to conventional treatment (31). The identification of
anti-inflammatory properties of HDAC and BET inhibitors
has generated great interest in the therapeutic potential of
targeting epigenetic mechanisms in many inflammatory and
infectious disorders, including periodontitis (32–34). Indeed,
pharmacological modulators of histone acetylation protected
against pathology in animal models of periodontal disease (21,
35). In particular, the BET inhibitor JQ1 has shown potent anti-
inflammatory and bone-protective activity (21). Here, we show
for the first time that BET bromodomain proteins are important
regulators of resident gingival cell activation in response to P.
gingivalis and inflammatory cytokines, and that small molecule
BET inhibitors suppress production of cytokines, chemokines,
and other mediators of inflammation by GFs and GECs from
periodontitis patients.
Destruction of the gingival connective tissue, periodontal
ligament, and alveolar bone in periodontitis is a consequence
of a futile attempt by the host immune response to eradicate
microbial pathogens (2). Resident gingival cells contribute to this
vicious circle of chronic inflammation by secreting a plethora
of inflammatory mediators, including cytokines (IL-6, IL-1β),
chemokines (IL-8, CCL2, CCL5, CXCL10, CCL20), matrix-
degrading enzymes (MMP1,MMP3,MMP9), and prostaglandins
(5). Elevated levels of these mediators are present in gingival
tissue and/or gingival crevicular fluid from periodontitis patients,
correlating with disease severity (5, 36, 37), and studies in
animal models show that genetic ablation or pharmacological
targeting of IL-6 or IL-1β ameliorates pathology in experimental
periodontitis (38). Our data provide evidence that BET proteins
are required for transcriptional induction of key inflammatory
molecules in GFs and GECs infected with P. gingivalis and
thus represent a potential therapeutic target for modulation of
the host immune response. Although quantitative differences
in the sensitivity of individual genes to BET inhibition were
noted, our observations are consistent with the broad anti-
inflammatory activity of BET inhibitors reported in synovial
fibroblasts and in airway epithelial cells (39, 40). While our
data suggest that suppression of GF and GEC inflammatory
activation by BET inhibitors is stimulus-independent, future
studies should analyze the role of BET proteins in gingival
cell response to a complex dental biofilm containing other oral
pathogens, such as Fusobacterium nucleatum, Tanerella forsythia,
and Treponema denticola. In this regard it is noteworthy that
JQ1 attenuated gastric inflammation and immune cell infiltration
in mice infected with Helicobacter pylori (41), indicating its
immunosuppressive potential in chronic infections caused by
Gram-negative pathogenic bacteria.
BET proteins regulate cellular activation not only at the
gene promoter level, but also through chromatin-independent
mechanisms. BRD4 binds acetylated lysine-310 of the p65 NF-κB
subunit, enhancing its transcriptional activity and thus acting as
a coactivator of NF-κB-dependent genes (26). In macrophages,
BRD4 also modulates NF-κB signaling through translational
control of IκBα resynthesis (42), whereas in endothelial cells BET
inhibition blocks early events in NF-κB activation as well as p38
and JNK MAPK phosphorylation (27). These mechanisms are,
however, cell type-specific and apparently not operational in GFs
based on our analyses of MAPK, IκBα, and NF-κB p65 activation.
While it remains to be determined if BET inhibition also fails
to affect NF-κB transcriptional activity and binding to specific
gene promoters in GFs, our findings are consistent with studies
of synovial fibroblasts fromRApatients demonstrating the lack of
effect of I-BET151 on NF-κB andMAPK signaling pathways (40).
We also show that de novo synthesis of repressor proteins is not
required for suppression of inflammatory genes by I-BET151 in
GFs and GECs, in line with observations in human macrophages
(17). Collectively, these results argue against indirect or signaling
pathway-dependent effects of BET inhibition in gingival cells
and suggest that interference with direct interaction of BET
proteins with acetylated histones at gene promoters is most
likely responsible for the observed suppression of inflammatory
mediator transcriptional induction. Although potential off-target
effects of BET inhibitors cannot be ruled out based on our studies,
extensive screening of these compounds failed to identify any
significant effects on non-BET protein targets (13, 43).
Among the analyzed inflammatory genes, expression of
CCL20 was selectively upregulated by I-BET151 and JQ1 in
some experimental conditions, particularly in GECs. CCL20
may play a dual role in periodontitis. As a chemoattractant
for immature dendritic cells and Th17 cells, CCL20 may
contribute to the chronicity of inflammation by facilitating
immune cell recruitment and accumulation (37). On the other
hand, CCL20 displays direct microbicidal activity against Gram-
positive and Gram-negative bacteria through its antimicrobial
regions structurally related to human β-defensin-2 (44). CCL20
induction by BET inhibitors could therefore facilitate bacterial
elimination by innate immune mechanisms. It remains to
be verified if CCL20 exerts antimicrobial activity against P.
gingivalis or other oral pathogens, and whether this mechanism is
operational in the inflamed gingival tissue during periodontitis.
While the exact role of bromodomain proteins in CCL20
regulation has yet to be investigated, HDAC inhibitors have
also been shown to promote CCL20 production by GECs and
intestinal epithelial cells (45, 46), suggesting a critical role for
histone acetylation in CCL20 transcriptional regulation that
requires detailed studies at the gene promoter level.
The idea that BET inhibitors may display clinical activity in
periodontal disease is also supported by recent evidence that
N-methyl-2-pyrrolidone (NMP), a component of dental barrier
membranes used in dental procedures, displays bromodomain
inhibitory activity (47). While initially thought to lack biological
activity, it was later discovered that NMP displays anti-
inflammatory and anti-osteoclastogenic activity similar to the
effects of BET inhibitors (48, 49). The efficacy of NMP-based
dental barrier membranes in periodontal tissue regeneration
could therefore be partly attributed to their ability to inhibit
BET bromodomains (50), a possibility that should be addressed
in future studies directly comparing NMP and BET inhibitor
activity in periodontitis models. These observations, together
with the results of our study and the initial proof of principle
obtained in an animal model (21), indicate that specific targeting
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of epigenetic reader proteins from the BET family may block
the excessive inflammatory mediator production by multiple cell
types important in the pathogenesis of periodontitis and reduce
the significant morbidity associated with periodontal disease.
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